Adlyxin

Chemical Namelixisenatide
Dosage FormInjection (subcutaneous; 50 mcg/mL, 100 mcg/mL)
Drug ClassReceptor agonists
SystemEndocrine
CompanySanofi-Aventis
Approval Year2016

Indication

  • To improve glycemic control in adults with type 2 diabetes mellitus.
Last updated on 10/26/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Adlyxin (lixisenatide) Prescribing Information 2019Sanofi-aventis U.S. LLC, Bridgewater, NJ